Press Releases

Date Title
Toggle Summary Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results
SAN DIEGO , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021 financial results
Toggle Summary Kura Oncology to Participate in SVB Leerink Global Healthcare Conference
SAN DIEGO , Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the 11 th Annual SVB Leerink Global Healthcare
Toggle Summary Kura Oncology Expands Leadership Team with Key Promotions
– Expanded leadership team to support and advance the Company's rapid growth – SAN DIEGO , Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today
Toggle Summary Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia
– FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome – – KOMET-001 study to resume screening and enrollment of new patients – – Encouraging safety, tolerability and clinical activity observed among patients on study – SAN DIEGO , Jan.
Toggle Summary Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
– Preclinical data suggest HRAS and PI3Kα are co-dependent oncogenes in HNSCC – – Combination has potential to address up to 50% of patients with HNSCC – – Initial cohort comprised of patients with PIK3CA-dependent HNSCC – SAN DIEGO , Dec. 16, 2021 (GLOBE NEWSWIRE) --  Kura Oncology, Inc.
Toggle Summary Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma
– Overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, an aggressive form of T-cell lymphoma – – Results presented at ASH underscore potential of farnesyl transferase inhibition to drive clinical benefit in cancer patients with high unmet need –
Toggle Summary Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax
– New findings presented at ASH support development strategy for KO-539 in KMT2A-rearranged and NPM1-mutant AML – SAN DIEGO , Dec. 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines
Toggle Summary Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
Management to host webcast and conference call today at 8:30 a.m. ET SAN DIEGO , Nov. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced
Toggle Summary Kura Oncology to Participate in Two Upcoming Investor Conferences
SAN DIEGO , Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer,
Toggle Summary Kura Oncology Reports Third Quarter 2021 Financial Results
– Continued enrollment in Phase 1b study of menin inhibitor KO-539 in NPM1-mutant and KMT2A-rearranged relapsed/refractory AML – – ASH presentation to highlight molecular mechanisms of activity for KO-539 and potential for synergistic activity in combination with venetoclax – – First clinical site